医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Elekta Ltd and Medical Intelligence Medizintechnik GmbH defend claims by humediQ GmbH

2014年12月03日 AM04:14
このエントリーをはてなブックマークに追加


 

CRAWLEY, United Kingdom

Regulatory News:

humediQ GmbH has initiated legal proceedings against two companies in the Elekta (STO:EKTAB) (EKTA-B.ST) group.

The dispute relates to an agreement from October 2011 for exclusive supply of Identify™ under the Elekta label. Identify is a patient identification and setup verification product.

Recently, a dispute arose between Elekta and humediQ relating to certain terms of the agreement. Now, humediQ is claiming damages from Elekta for an amount of approximately EUR 16 million.

Elekta believes that the claims have no merit and intends to defend them vigorously and assert counterclaims against humediQ.

# # #

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 20:00 CET on December 2, 2014.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.

This information was brought to you by Cision http://news.cision.com

CONTACT

For further information, please contact:
Elekta AB
Gert
van Santen, +31 653 561 242
Group Vice President Corporate
Communications
gert.vansanten@elekta.com
Time
zone: CET: Central European Time

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表